Epilepsy and the risk of COVID‐19‐related hospitalization and death: A population study

Abstract

AbstractObjectivePeople with epilepsy (PWE) may be at an increased risk of severe COVID‐19. It is important to characterize this risk to inform PWE and for future health and care planning. We assessed whether PWE were at higher risk of being hospitalized with, or dying from, COVID‐19.MethodsWe performed a retrospective cohort study using linked, population‐scale, anonymized electronic health records from the SAIL (Secure Anonymised Information Linkage) databank. This includes hospital admission and demographic data for the complete Welsh population (3.1 million) and primary care records for 86% of the population. We identified 27 279 PWE living in Wales during the study period (March 1, 2020 to June 30, 2021). Controls were identified using exact 5:1 matching (sex, age, and socioeconomic status). We defined COVID‐19 deaths as having International Classification of Diseases, 10th Revision (ICD‐10) codes for COVID‐19 on death certificates or occurring within 28 days of a positive SARS‐CoV‐2 polymerase chain reaction (PCR) test. COVID‐19 hospitalizations were defined as having a COVID‐19 ICD‐10 code for the reason for admission or occurring within 28 days of a positive SARS‐CoV‐2 PCR test. We recorded COVID‐19 vaccinations and comorbidities known to increase the risk of COVID‐19 hospitalization and death. We used Cox proportional hazard models to calculate hazard ratios.ResultsThere were 158 (.58%) COVID‐19 deaths and 933 (3.4%) COVID‐19 hospitalizations in PWE, and 370 (.27%) deaths and 1871 (1.4%) hospitalizations in controls. Hazard ratios for COVID‐19 death and hospitalization in PWE compared to controls were 2.15 (95% confidence interval [CI] = 1.78–2.59) and 2.15 (95% CI = 1.94–2.37), respectively. Adjusted hazard ratios (adjusted for comorbidities) for death and hospitalization were 1.32 (95% CI = 1.08–1.62) and 1.60 (95% CI = 1.44–1.78).SignificancePWE are at increased risk of being hospitalized with, and dying from, COVID‐19 when compared to age‐, sex‐, and deprivation‐matched controls, even when adjusting for comorbidities. This may have implications for prioritizing future COVID‐19 treatments and vaccinations for PWE.